EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Evaluation of a Synthetic Retinoid, Ellorarxine, in the NSC-34 Cell Model of Motor Neuron Disease

Olivia Escudier, Yunxi Zhang, Andrew Whiting iD, Paul Chazot iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25189764 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Olivia Escudier und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biosciences, Wolfson Research Institute for Health and Wellbeing, Durham University, Durham DH1 3LE, UK. Hauptthemen laut MEDLINE: Neuroprotective Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease worldwide and is characterized by progressive muscle atrophy. There are currently two approved treatments, but they only relieve symptoms briefly and do not cure the disease. The main hindrance to research is the complex cause of ALS, with its pathogenesis not yet fully elucidated. Retinoids (vitamin A derivatives) appear to be essential in neuronal cells and have been implicated in ALS pathogenesis. This study explores 4-[2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydroquinoxalin-2-yl)ethylnyl]benzoic acid (Ellorarxine, or DC645 or NVG0645), a leading synthetic retinoic acid, discussing its pharmacological mechanisms, neuroprotective properties, and relevance to ALS. The potential therapeutic effect of Ellorarxine was analyzed in vitro using the WT and SOD1G93A NSC-34 cell model of ALS at an administered concentration of 0.3–30 nM. Histological, functional, and biochemical analyses were performed. Elorarxine significantly increased MAP2 expression and neurite length, increased AMPA receptor GluA2 expression and raised intracellular Ca2+ baseline, increased level of excitability, and reduced Ca2+ spike during depolarization in neurites. Ellorarxine also displayed both antioxidant and anti-inflammatory effects. Overall, these results suggest Ellorarxine shows relevance and promise as a novel therapeutic strategy for treatment of ALS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neuroprotective AgentsAnimalsMiceRetinoidsAmyotrophic Lateral SclerosisCell LineHumansReceptors, AMPAMotor NeuronsBenzoatesMotor Neuron DiseaseCalciumNeurites

Stichwörter der Autor:innen

Amyotrophic lateral sclerosisDC645Ellorarxineneurodegenerationneuroinflammationneuroprotective effectsretinoid

Substanzen

Neuroprotective AgentsRetinoidsReceptors, AMPABenzoatesCalciumglutamate receptor ionotropic, AMPA 2

Autor:innen und Institutionen

  • Department of Biosciences, Wolfson Research Institute for Health and Wellbeing, Durham University, Durham DH1 3LE, UK.
  • Department of Chemistry, Science Laboratories, Durham University, Durham DH1 3LE, UK.

ORCID-Profile: Andrew Whiting, Paul Chazot

Zitieren

APA

Escudier, O., Zhang, Y., Whiting, A., & Chazot, P. (2024). Evaluation of a Synthetic Retinoid, Ellorarxine, in the NSC-34 Cell Model of Motor Neuron Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25189764

Vancouver

Escudier O, Zhang Y, Whiting A, Chazot P. Evaluation of a Synthetic Retinoid, Ellorarxine, in the NSC-34 Cell Model of Motor Neuron Disease. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25189764

BibTeX
@article{Escudier2024,
  author = {Escudier, Olivia and Zhang, Yunxi and Whiting, Andrew and Chazot, Paul},
  title = {Evaluation of a Synthetic Retinoid, Ellorarxine, in the NSC-34 Cell Model of Motor Neuron Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25189764}
}
Kostenlos starten →